paper.io

agar io

wowcappadocia.com cappadocia tours
cappadocia-hotels.com cappadocia hotels
caruscappadocia.com cappadocia hotel
brothersballoon.com cappadocia balloon
balloon-rides.net cappadocia balloon flights

wormax io

rolex replica

Comparison in Efficacy and Safety of Koklan Mixture Formula 3 and Diclofenac for Pain Relieving in Primary Knee Osteoarthritis

Abstract

Renu Pongsaree, Yongyudh Vajaradul, Supalak Fakkham, Thavatchai Kamoltham

Knee Osteoarthritis is a common disease in aging society. In general, Diclofenac which belongs to Nonsteroidal Anti-inflammatory drugs, has analgesic and Antiinflammation effects. Although Diclofenac is often prescribed, it conveys high incidence of side effects especially in stomach ulcer. Therefore, the researcher realizes the importance of using the Koklan Mixture Formula 3 which is National Drug Information to replace the using of foreign medicine. The objective of this research was 1) to study comparison of efficacy of the Koklan Mixture Formula 3 and Diclofenac 2) to study safety of the Koklan Mixture Formula 3 and Diclofenac in reducing pain in primary osteoarthritis 3) to study the effectiveness of the Koklan Mixture Formula 3. Research methodology was a Randomize-double blinded, controlled trial at Suan Sunandha Medical Clinic, with criteria for selection of volunteers aged 50-70 years of knee pain no more than moderate using randomize-double blinded, controlled trial. According to the Oxford Knee Score evaluation, 68 subjects using random sampling method, blocked Randomization divided into 2 groups, consisting of 34 patients received the Koklan Mixture Formula 3 dose 30 cc before 3 meals and 34 received Diclofenac 25 mg after 3 meals for 14 days. In this study showed that the Koklan Mixture Formula 3 and Diclofenac were efficient and safe for the treatment of primary knee osteoarthritis and there were no differences statistically significant. Beside Koklan formular 3 also has effect on muscle relaxation, reduce edema and the blood nourishment.

Most Viewed Articles
  • Dental Development between Assisted Reproductive Therapy (Art) and Natural Conceived Children: A Comparative Pilot Study Norzaiti Mohd Kenali, Naimah Hasanah Mohd Fathil, Norbasyirah Bohari, Ahmad Faisal Ismail, Roszaman Ramli SRP. 2020; 11(1): 01-06 » doi: 10.5530/srp.2020.1.01
  • Psychometric properties of the World Health Organization Quality of life instrument, short form: Validity in the Vietnamese healthcare context Trung Quang Vo*, Bao Tran Thuy Tran, Ngan Thuy Nguyen, Tram ThiHuyen Nguyen, Thuy Phan Chung Tran SRP. 2020; 11(1): 14-22 » doi: 10.5530/srp.2019.1.3
  • A Review of Pharmacoeconomics: the key to “Healthcare for All” Hasamnis AA, Patil SS, Shaik Imam, Narendiran K SRP. 2019; 10(1): s40-s42 » doi: 10.5530/srp.2019.1s.21
  • Deuterium Depleted Water as an Adjuvant in Treatment of Cancer Anton Syroeshkin, Olga Levitskaya, Elena Uspenskaya, Tatiana Pleteneva, Daria Romaykina, Daria Ermakova SRP. 2019; 10(1): 112-117 » doi: 10.5530/srp.2019.1.19
Most Downloaded
  • Dental Development between Assisted Reproductive Therapy (Art) and Natural Conceived Children: A Comparative Pilot Study Norzaiti Mohd Kenali, Naimah Hasanah Mohd Fathil, Norbasyirah Bohari, Ahmad Faisal Ismail, Roszaman Ramli SRP. 2020; 11(1): 01-06 » doi: 10.5530/srp.2020.1.01
  • Manilkara zapota (L.) Royen Fruit Peel: A Phytochemical and Pharmacological Review Karle Pravin P, Dhawale Shashikant C SRP. 2019; 10(1): 11-14 » doi: 0.5530/srp.2019.1.2
  • Pharmacognostic and Phytopharmacological Overview on Bombax ceiba Pankaj Haribhau Chaudhary, Mukund Ganeshrao Tawar SRP. 2019; 10(1): 20-25 » doi: 10.5530/srp.2019.1.4
  • A Review of Pharmacoeconomics: the key to “Healthcare for All” Hasamnis AA, Patil SS, Shaik Imam, Narendiran K SRP. 2019; 10(1): s40-s42 » doi: 10.5530/srp.2019.1s.21
  • A Prospective Review on Phyto-Pharmacological Aspects of Andrographis paniculata Govindraj Akilandeswari, Arumugam Vijaya Anand, Palanisamy Sampathkumar, Puthamohan Vinayaga Moorthi, Basavaraju Preethi SRP. 2019; 10(1): 15-19 » doi: 10.5530/srp.2019.1.3